001     170402
005     20240229133712.0
024 7 _ |a 10.1182/blood.2021011557
|2 doi
024 7 _ |a pmid:34424946
|2 pmid
024 7 _ |a 0006-4971
|2 ISSN
024 7 _ |a 1528-0020
|2 ISSN
024 7 _ |a altmetric:112248681
|2 altmetric
037 _ _ |a DKFZ-2021-01909
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Zanetti, Costanza
|b 0
245 _ _ |a The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13.
260 _ _ |a Washington, DC
|c 2021
|b American Society of Hematology
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1642421861_11679
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2021 Nov 11;138(19):1870-1884
520 _ _ |a B-cell acute lymphoblastic leukemia (B-ALL) occurs most commonly in children, while chronic myeloid leukemia (CML) is more frequent in adults. The myeloid bias of hematopoiesis in elderly individuals has been considered causative, but the age of the bone marrow (BM) microenvironment (BMM) may be contributory. Using various murine models of B-ALL in young versus old mice, we recapitulated B-ALL preponderance in children versus adults. We showed differential effects of young versus old BM macrophages on B-ALL cell function. Molecular profiling using RNA- and ATAC-seq revealed pronounced differences in young versus old BMM-derived macrophages and enrichment for gene sets associated with inflammation. In concordance with the role of C-X-C motif chemokine (CXCL) 13 for disease-associated B cell chemoattraction, we found CXCL13 to be highly expressed in young macrophages on a translational compared to a transcriptional level. Inhibition of CXCL13 in BM macrophages impaired leukemia cell migration and decreased the proliferation of cocultured B-ALL cells, while recombinant CXCL13 increased pAKT and B-ALL cell expansion. Pretreatment of B-ALL-initiating cells with CXCL13 accelerated B-ALL progression. Deficiency of Cxcr5, the receptor for CXCL13, on B-ALL-initiating cells prolonged murine survival, while high expression of CXCR5 in pediatric B-ALL may predict central nervous system relapse. CXCL13 staining was increased in bone sections from pediatric compared to adult B-ALL patients. Taken together, our study shows that the age of the BMM and, in particular, BM macrophages influence the leukemia phenotype. The CXCR5-CXCL13-axis may act as prognostic marker and an attractive novel target for the treatment of B-ALL.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
700 1 _ |a Kumar, Rahul
|b 1
700 1 _ |a Ender, Joscha
|b 2
700 1 _ |a Godavarthy, Parimala S
|b 3
700 1 _ |a Hartmann, Mark
|0 P:(DE-He78)6bd32b26ed14ffc9746ba2d4816e0559
|b 4
|u dkfz
700 1 _ |a Hey, Joschka
|0 P:(DE-He78)198a73f54b40192a2fdc2bf53ba7ca27
|b 5
|u dkfz
700 1 _ |a Breuer, Kersten
|0 P:(DE-He78)75efcd61c13c2fbe457cdf3454ef486c
|b 6
|u dkfz
700 1 _ |a Weissenberger, Eva S
|b 7
700 1 _ |a Minciacchi, Valentina R
|0 0000-0002-9296-9403
|b 8
700 1 _ |a Karantanou, Christina
|0 0000-0002-2161-914X
|b 9
700 1 _ |a Gu, Zhaohui
|0 0000-0003-1581-1327
|b 10
700 1 _ |a Roberts, Kathryn G
|b 11
700 1 _ |a Metzler, Markus
|0 0000-0002-4523-1676
|b 12
700 1 _ |a Stock, Wendy
|b 13
700 1 _ |a Mullighan, Charles G
|0 0000-0002-1871-1850
|b 14
700 1 _ |a Bloomfield, Clara D
|b 15
700 1 _ |a Filmann, Natalie
|b 16
700 1 _ |a Bankov, Katrin
|b 17
700 1 _ |a Hartmann, Sylvia
|0 0000-0003-3424-1091
|b 18
700 1 _ |a Hasserjian, Robert P
|0 0000-0002-7753-0697
|b 19
700 1 _ |a Cousins, Antony F
|0 0000-0003-1516-2515
|b 20
700 1 _ |a Halsey, Christina
|0 0000-0001-5449-5246
|b 21
700 1 _ |a Plass, Christoph
|0 P:(DE-He78)4301875630bc997edf491c694ae1f8a9
|b 22
|u dkfz
700 1 _ |a Lipka, Daniel
|0 P:(DE-He78)c403a040c97f91902a7d31b93859f9fc
|b 23
|u dkfz
700 1 _ |a Krause, Daniela S
|0 0000-0003-3603-1119
|b 24
773 _ _ |a 10.1182/blood.2021011557
|g p. blood.2021011557
|0 PERI:(DE-600)1468538-3
|n 19
|p 1870-1884
|t Blood
|v 138
|y 2021
|x 1528-0020
909 C O |p VDB
|o oai:inrepo02.dkfz.de:170402
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)6bd32b26ed14ffc9746ba2d4816e0559
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)198a73f54b40192a2fdc2bf53ba7ca27
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)75efcd61c13c2fbe457cdf3454ef486c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)4301875630bc997edf491c694ae1f8a9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 23
|6 P:(DE-He78)c403a040c97f91902a7d31b93859f9fc
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-01-28
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BLOOD : 2019
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2021-01-28
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2021-01-28
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b BLOOD : 2019
|d 2021-01-28
920 1 _ |0 I:(DE-He78)B370-20160331
|k B370
|l Epigenomik
|x 0
920 1 _ |0 I:(DE-He78)B340-20160331
|k B340
|l Translationale Medizinische Onkologie
|x 1
920 1 _ |0 I:(DE-He78)W620-20160331
|k W620
|l German Human GEnome-Phenome Archive
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B370-20160331
980 _ _ |a I:(DE-He78)B340-20160331
980 _ _ |a I:(DE-He78)W620-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21